文献速递骨显像与常规 SPECT肿瘤 PET/CT

68Ga-DOTA-伊班膦酸PET/CT在化疗致唾液腺功能减退患者中的应用

68 Ga-DOTA-Ibandronic Acid PET/CT in a Patient With Chemotherapy-Induced Salivary Gland Hypofunction.
PubMed 文献 · Clin Nucl Med · 2024-02-28

本文报告一例胆管癌多发骨转移患者的68Ga-DOTA-伊班膦酸PET/CT表现:骨转移灶摄取增高,同时双侧唾液腺呈对称性弥漫性摄取增高;99mTcO4-唾液腺显像显示唾液腺功能受损。提示DOTA-IBA除靶向骨转移外,骨外病变也可出现摄取增高。

要点

  • 68Ga-DOTA-IBA PET/CT可显示骨转移灶摄取增高。
  • 本例双侧唾液腺出现对称性弥漫性DOTA-IBA摄取增高。
  • 99mTcO4-唾液腺显像证实唾液腺功能受损。

核心结论

  • 68Ga-DOTA-IBA除在骨转移灶摄取增高外,骨外病变如唾液腺也可出现摄取增高。

研究设计与样本

  • 本文为病例报告,报告一例胆管癌多发骨转移患者的68Ga-DOTA-IBA PET/CT及99mTcO4-唾液腺显像结果。

主要发现

  • 68Ga-DOTA-IBA PET/CT显示骨转移灶DOTA-IBA摄取增高。
  • 68Ga-DOTA-IBA PET/CT显示双侧唾液腺对称性弥漫性DOTA-IBA摄取增高。
  • 99mTcO4-唾液腺显像显示唾液腺功能受损。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DOTA-ibandronic acid (IBA) is a novel precursor targeting bone metastasis. It can be radiolabeled with 68 Ga for the diagnosis of bone metastases. However, extraosseous lesions can also show increased DOTA-IBA uptake. We report the 68 Ga-DOTA-IBA PET/CT findings in a case with cholangiocarcinoma with multiple bone metastases. 68 Ga-DOTA-IBA PET/CT revealed increased uptake of DOTA-IBA in bone metastases. Besides, symmetrical and diffuse increased DOTA-IBA uptake in bilateral salivary glands was observed. 99m TcO 4- salivary gland scintigraphy showed impaired salivary gland function.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu Y, Ding H, Zhang T, et al. 68 Ga-DOTA-Ibandronic Acid PET/CT in a Patient With Chemotherapy-Induced Salivary Gland Hypofunction. Clin Nucl Med. 2024. PMID: 38465977. doi:10.1097/RLU.0000000000005133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。